You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 147 No. 12, December 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Ranitidine Protects Against Gastroduodenal Mucosal Damage Associated With Chronic Aspirin Therapy

Jesse M. Berkowitz, MD; Paula R. Rogenes, PhD; Jeffrey T. Sharp, MS; Christopher W. Warner, PhD

Arch Intern Med. 1987;147(12):2137-2139.


Abstract

• A randomized, double-blind, placebo-controlled study examined whether concomitant administration of ranitidine could protect against the gastroduodenal mucosal damage associated with long-term aspirin therapy in healthy men. Twenty-four subjects received ranitidine (150 mg twice daily) plus aspirin (650 mg four times daily), and 19 received placebo twice daily plus aspirin (650 mg four times daily) for four weeks. Gastric injury and duodenal injury were assessed separately according to a numerical rating scale for incidence and severity of lesions observed during endoscopic examinations at baseline and after four weeks of treatment. The ranitidine/aspirin group had significantly less mucosal damage in the stomach and duodenum than the placebo/aspirin group. Mean serum salicylate levels were similar between treatment groups after two and four weeks of aspirin therapy. Therefore, the protective effect of ranitidine was achieved with no compromise in salicylate absorption.

(Arch Intern Med 1987;147:2137-2139)



Author Affiliations

From the Department of Medicine, Mercy Hospital, Rockville Centre, NY, and the School of Medicine, State University of New York at Stony Brook (Dr Berkowitz), and Glaxo Inc, Research Triangle Park, NC (Drs Rogenes and Warner and Mr Sharp).


Footnotes

Accepted for publication Sept 8, 1987.

Reprint requests to the Department of Medicine, Mercy Hospital, Rockville Centre, NY 11570 (Dr Berkowitz).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs
Wolfe et al.
NEJM 1999;340:1888-1899.
FULL TEXT  

Prevention of Nonsteroidal Anti-inflammatory Drug--Induced Gastrointestinal Mucosal Injury: A Meta-analysis of Randomized Controlled Clinical Trials
Koch et al.
Arch Intern Med 1996;156:2321-2332.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.